Administrative Core

由HIV-1引起的获得性免疫缺陷综合症(AIDS)是#年的主要死亡原因。 非洲是世界第四大死因。该IPCAVD正在开发艾滋病毒/艾滋病疫苗， 使用DNA用于启动和MVA用于加强(DNA/MVA疫苗)，以及更简单和最终更容易 部署这些疫苗的形式，将MVA用于启动和加强(MVA/MVA疫苗)。这两个 DNA和MVA疫苗使用单一载体表达病毒样颗粒(VLP)。这个IPCAVD试图建立 将佐剂GM-CSF插入到这些产物中，在顺式系统中表达。在临床前研究中，GMCSF的共表达 极大地加强了保护。IPCAVD的一个中心假设是GM-CSF改善了 通过增强粘膜中激发的T细胞和抗体反应的存在来保护。C分支HIV-1是 南部非洲和亚洲部分地区的地方病约占全球感染人数的一半， 在印度，90%的病例发生在一个感染迅速传播的国家，这个国家已经超过了南非 病例总数。IPCAVD的疫苗开发工作重点是开发一种C分支 印度的疫苗。 这一行政核心有五个具体目标： ？为项目提供全面协调 ？提供数据管理和统计支持 ？为知识产权申请和谈判提供后勤支持 ？协助出版 ·维持预算和财政监督 项目主任哈里特·罗宾逊博士将领导行政核心。她已经证明了 领导IPCAVD计划和将概念从试验台转移到早期临床试验的经验 通过HVTN。

The acquired immunodeficiency syndrome (AIDS) caused by HIV-1 is the leading cause of death in Africa and the fourth leading cause of death worldwide. This IPCAVD is developing HIV/AIDS vaccines that use DNA for priming and MVA for boosting (DNA/MVA vaccine) as well as a simpler an ultimately easier to deploy form of these vaccines, the use of MVA for both priming and boosting (MVA/MVA vaccine). Both the DNA and MVA vaccines use single vectors to express virus like particles (VLP). This IPCAVD seeks to build GM-CSF, an adjuvant, into these products for expression in cis. In preclinical studies, co-expression of GMCSF has substantially enhanced protection. A central hypothesis for the IPCAVD is that GM-CSF improves protection by enhancing the mucosal presence of elicited T cell and Ab responses. Clade C HIV-1 which is endemic in southern Africa and parts of Asia accounts for about one half of the infections worldwide and >90% of the cases in India, a country with a rapidly spreading infection that has surpassed South Africa in its total number of cases. The vaccine development effort of this IPCAVD is focused on developing a clade C vaccine for India. This administrative core has five specific aims: ¿ Provide overall co-ordination for the Program ¿ Provide data management and statistical support ¿ Provide logistical support for intellectual property filings and negotiations ¿ Assist with publications ¿ Maintain budgets and fiscal oversight Dr. Harriet Robinson, the Program Director, will lead the Administrative core. She has demonstrated experience in leading IPCAVD programs and moving concepts from the bench to early phase clinical trials through the HVTN.